Protalix BioTherapeutics Inc (DE) — Quarterly Financial Statistics (NYSE:PLX) | MetaTrader

Open full chart

Financials

Overview 明細書 Statistics

Quarterly Annual

Cash from operating activities 4.11 M3.99 M5.06 M5.23 M3.73 M 18.01 M Cash from investing activities 18.75 M-15.32 M312 K438 K504 K -14.07 M Cash from financing activities 005.08 M4.1 M0 — Free cash flow 4.02 M3.57 M4.75 M4.8 M3.23 M 16.35 M

Protalix BioTherapeutics Inc (DE)

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.

ニュース

Brazil judge overrules decisions suspending changes to meal voucher system

A March Decision That Could Change Protalix’s Outlook (NYSE:PLX)

Pluxee社とEdenred社、好調な業績と見通しを受け株価急騰

Pluxee, Edenred shares jump after upbeat results and outlook

Pluxee 2026年度第1四半期：ブラジルの課題の中でも9%の収益成長

Pluxee posts 9% growth in Q1; confirms 2026 outlook despite Brazil headwinds

プロタリックス、制御不能な痛風治療に焦点を当てた2026年戦略を概説

Tuesday’s Insider Activity: Key Execs Make Notable Trades

プロタリックス・バイオセラピューティクスのCEOバシャン・ドロール氏が10万ドル超の株式を購入

BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN)

プロタリックスとセカルナ、希少腎疾患治療薬開発で提携

Protalix and Secarna partner to develop rare kidney disease treatments